Goldman Sachs initiated coverage of Exelixis (EXEL) with a Buy rating and $47 price target The recent share pullback creates an attractive entry point, the analyst tells investors in a research note. The firm expects continued Cabometyx commercial execution and believes the pending zanzalintinib data will solidify Exelixis’ longer term outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis assumed with an Equal Weight at Barclays
- Exelixis initiated with an Equal Weight at Barclays
- Exelixis Advances Phase 1 Study of XL309 for Advanced Solid Tumors
- Exelixis Advances in Neuroendocrine Tumor Treatment with New Clinical Trial
- Exelixis’s Promising Growth Potential and Strategic Expansion Justify Buy Rating